Buy Mod GRF 1-29 CJC 1295 No DAC | 2MG

Paradigm Peptides manufactures CJC-1295 without DAC for sale at the highest quality and potency available. Researchers commonly refer to CJC-1295 without DAC as modified GRF 1-29. This particular variation of the synthetic peptide stimulates growth hormone production according to most studies.

Application:	Stimulates growth hormone production
CAS:	863288-34-0
Molecular Weight:	3367.954 g·mol
Chemical Formula:	C152H252N44O42
Chemical Name:	L-Tyrosyl-D-alanyl-L-alpha-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-glutaminyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-alpha-aspartyl-L-isoleucyl-L-leucyl-L-seryl-L-argininamide
Synonyms:	Mod GRF(1-29), CJC-1295 W/O DAC. CJC-1295 Acetate
Storage:	Minimize open air exposure, store in a cool dry place.
Stability:	2 years
Purity:	99%
Solubility:	Soluble to water at rate of 0.1mg/ml
Physical Form:	fine powder in glass vial
Specifications:	2mg vial
Terms:	The products we offer are intended for laboratory research use only. You will need to purchase Bacteriostatic water separately.

Mod GRF 1-29, also known as CJC 1295 without DAC (Drug Affinity Complex), is a synthetic peptide that falls under the category of growth hormone-releasing hormones (GHRH). It is a modified version of the naturally occurring peptide hormone, Growth Hormone Releasing Hormone (GHRH), specifically its 1-29 amino acid sequence. This modification enhances its stability and potency, making it more effective for therapeutic and research purposes.

Peptide Structure

Mod GRF 1-29 consists of 29 amino acids, with its sequence being Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. This sequence has been modified from the full-length GHRH to enhance its stability and bioavailability in the body. The modification involves replacing the naturally occurring amino acids with D-amino acids and incorporating other structural changes to increase its half-life and activity.

Precursors and Initiators:

• Tyr (Tyrosine)
• D-Ala (D-Alanine)

These amino acids serve as precursors and initiators in Mod GRF 1-29. Tyrosine acts as a precursor for neurotransmitters and hormones and is crucial for receptor binding and intracellular signaling cascades. D-Alanine enhances peptide stability and resistance to enzymatic degradation, initiating structural integrity.

Structural Integrity and Receptor Binding:

• Asp (Aspartic Acid)
• Arg (Arginine)
• Lys (Lysine)
• Ala (Alanine)
• NH2 (Amide Group)

These amino acids contribute to the structural integrity and receptor binding of Mod GRF 1-29. Aspartic acid contributes to structural integrity and receptor binding. Arginine and lysine likely facilitate receptor binding and intracellular signaling. Alanine plays a role in maintaining structural integrity and receptor binding. The NH2 amide group stabilizes peptide structure, influencing receptor binding and signaling.

Role in Protein Synthesis and Function:

• Ile (Isoleucine)
• Phe (Phenylalanine)
• Thr (Threonine)
• Gln (Glutamine)
• Ser (Serine)
• Val (Valine)
• Leu (Leucine)
• Met (Methionine)

These amino acids contribute to protein synthesis and function within Mod GRF 1-29. Isoleucine contributes to the peptide’s overall structure and function. Phenylalanine may participate in receptor binding and intracellular signaling. Threonine and serine contribute to peptide structure and function. Glutamine potentially facilitates receptor binding and intracellular signaling. Valine likely contributes to peptide structure and function. Leucine may be involved in receptor binding and intracellular signaling. Methionine contributes to peptide structure and function.

Overall, each amino acid in Mod GRF 1-29 contributes to the peptide’s structure, stability, receptor binding affinity, and intracellular signaling properties, ultimately facilitating its function as a growth hormone-releasing hormone.

Primary Mechanism of Action

The mechanism of action of Mod GRF 1-29 revolves around stimulating the secretion of growth hormone (GH) from the pituitary gland, a critical regulator of growth, metabolism, and various physiological functions in animals.

Upon administration, Mod GRF 1-29 interacts with specific GHRH receptors located on somatotroph cells in the anterior pituitary gland. This interaction triggers intricate intracellular signaling pathways, culminating in the synthesis and release of GH into the bloodstream.

The GH release induced by Mod GRF 1-29 mirrors the pulsatile pattern observed naturally, crucial for sustaining normal physiological processes such as growth, metabolism, and tissue repair in animal models.

An advantageous aspect of Mod GRF 1-29 lies in its enhanced stability and prolonged activity within the body compared to full-length GHRH peptides. Structural alterations fortify the peptide against enzymatic degradation, extending its half-life and ensuring sustained GH stimulation in animal studies.

In addition to its pivotal role in GH regulation, Mod GRF 1-29 holds promise for therapeutic applications in animal models afflicted with GH deficiency, age-related decline in GH levels, and metabolic disorders. Furthermore, its efficacy in promoting lean muscle mass, reducing body fat, and hastening post-exercise recovery has garnered attention in veterinary and research communities.

Mod GRF 1-29 (CJC 1295 without DAC) emerges as a potent tool for stimulating GH secretion in animal models by targeting GHRH receptors in the pituitary gland. Its modified structure enhances stability and activity, rendering it valuable for animal research and therapeutic interventions aimed at modulating GH regulation and metabolism.

Normalized Growth In GHRH Knockout Mice

Exploring avenues for growth normalization, a study delved into the impact of Mod GRF 1-29 (CJC-1295), a synthetic analog of human growth hormone-releasing hormone (GHRH), in GHRH knockout (GHRHKO) mice. Administered at varying intervals, CJC-1295 effectively normalized body weight and length in GHRHKO mice, with once-daily administration showcasing optimal results. [2]

Mice treated every 48 and 72 hours exhibited increased body weight and length without full growth normalization. However, femur and tibia length remained within normal parameters with treatments every 24 and 48 hours. Notably, CJC-1295 administration induced an upsurge in total pituitary RNA and GH mRNA, signifying somatotroph cell proliferation. [2]

This study underscores the potential of Mod GRF 1-29 (CJC-1295) in maintaining normal body composition and growth in GHRHKO mice, offering insights into interval-dependent effects at longer dosing intervals.

Pulsatile Secretion Of Growth Hormone Persists During Continuous Stimulation By CJC-1295

Examining the intricacies of GH pulsatility, a study on rats elucidated the effects of CJC-1295, a synthetic GHRH analog, on GH secretion patterns and insulin-like growth factor-I (IGF-I) production. Following a single injection, GH pulsatility was meticulously evaluated through 20-minute blood sampling over a 12-hour period. [4]

The findings revealed that CJC-1295 bolstered GH secretion while preserving pulsatility, with basal GH levels experiencing a marked increase. This augmentation contributed to elevated GH secretion and IGF-I levels, underlining the therapeutic potential of long-acting GHRH preparations, such as CJC-1295, in individuals with intact pituitary GH secretory capability. [4]

Stability Of GRF Analogs In Porcine Plasma

In a bid to assess the resilience of growth-hormone releasing factor (GRF) analogs, a study conducted in porcine plasma scrutinized their stability. Through meticulous analysis utilizing high-performance liquid chromatography (HPLC), it was revealed that GRF(1-29)-NH2 faced rapid degradation in plasma, with a half-life (t1/2) of 13 minutes. [5]

Substituting Gly15 with Ala15 marginally extended the plasma half-life to 17 minutes, with [Ala15]GRF(3-29)-NH2 identified as the primary degradative fragment. Structural modifications, including side-chain cyclization and amino acid substitutions, demonstrated significant improvements in analog stability, suggesting promising avenues for enhancing their pharmacokinetic profiles. [5]

Therapeutic Applications of CJC 1295 W/O DAC

let’s explore additional therapeutic applications of Mod GRF 1-29 (CJC-1295) beyond those mentioned in the research findings:

Age-Related Growth Hormone Deficiency

In aging animals, a decline in growth hormone (GH) secretion is a common occurrence. Mod GRF 1-29 shows promise as a therapeutic tool for addressing age-related GH deficiency in animal models by stimulating GH secretion from the pituitary gland. By reinstating physiological GH levels, Mod GRF 1-29 may help alleviate symptoms associated with age-related decline, including diminished muscle mass, increased adiposity, reduced bone density, and decreased vigor.

Metabolic Disorders

GH dysregulation is implicated in various metabolic disorders seen in animals, including obesity, insulin resistance, and metabolic syndrome. Researchers have explored the potential of Mod GRF 1-29 to ameliorate metabolic parameters by enhancing GH secretion and modulating insulin sensitivity in animal models. By promoting lipid metabolism, reducing visceral fat accumulation, and enhancing glucose homeostasis, Mod GRF 1-29 may offer therapeutic benefits for animals with metabolic disorders, particularly those unresponsive to traditional treatments.

Muscle Wasting Disorders

Muscle wasting disorders, such as cachexia, sarcopenia, and muscular dystrophy, are characterized by progressive loss of muscle mass and function in animals. Mod GRF 1-29 holds promise as a therapeutic intervention for preserving muscle mass and function in animal models by stimulating GH secretion and promoting protein synthesis. Through its anabolic effects, Mod GRF 1-29 may help mitigate muscle wasting and improve physical function in animals with muscle-related disorders.

Frailty Syndrome

Frailty syndrome, marked by reduced physical resilience and increased susceptibility to adverse health outcomes, is prevalent among aging animals. Mod GRF 1-29 may serve as a therapeutic option for attenuating frailty in animals by enhancing muscle strength, endurance, and overall functional capacity. By augmenting GH secretion and fostering muscle growth, Mod GRF 1-29 has the potential to enhance frailty-related outcomes and improve the quality of life in aging animals.

Wound Healing and Tissue Repair

GH plays a pivotal role in wound healing and tissue repair processes by stimulating cell proliferation, collagen synthesis, and angiogenesis in animals. Mod GRF 1-29 may expedite wound healing and tissue regeneration in animals by boosting GH secretion and enhancing tissue remodeling processes. As a therapeutic adjunct, Mod GRF 1-29 holds promise for facilitating faster recovery from injuries, surgical interventions, and chronic wounds in animals.

Mod GRF 1-29 (CJC-1295) demonstrates therapeutic potential across a range of conditions relevant to animal health. By modulating GH secretion and exerting anabolic effects, Mod GRF 1-29 offers promising avenues for addressing age-related growth hormone deficiency, metabolic disorders, muscle wasting disorders, frailty syndrome, and wound healing processes in animal models. Further preclinical research and investigation are warranted to elucidate the efficacy, safety, and optimal dosing regimens of Mod GRF 1-29 in diverse therapeutic applications for animals.

CJC 1295 W/O DAC At Paradigm Peptides

Paradigm Peptides is a top-quality research chemical, peptide, and SARMs manufacturer based in the Midwest United States. We pride ourselves on providing the best products available. Each one of our products undergoes strict lab testing to ensure its efficacy, purity, and potency. Feel free to contact us.

*Disclaimer: The CJC-1295 without DAC currently listed on this site is sold for research use only. Not for human consumption. This product is not a drug, supplement, food or cosmetic and it may not be misused, sold, labeled or branded as such. These products are not intended to diagnose, treat, or cure any condition or disease. It is not intended for human consumption, and is for research purposes only.

Research:

[1] https://pubchem.ncbi.nlm.nih.gov/compound/56841945

[2] https://journals.physiology.org/doi/full/10.1152/ajpendo.00201.2006

[3] https://zenodo.org/record/1083962#.YXsbsJ7MIdU

[4] https://academic.oup.com/jcem/article/91/12/4792/2656274

[5] https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2007-1003601